Advancing prostate cancer diagnosis through next-generation ultrasound
Less Grey Imaging is a Scottish medical imaging technology company founded in October 2023 as a spinout from Heriot-Watt University in Edinburgh. Less Grey Imaging is developing ProViu, a novel ultrasound imaging platform for prostate cancer diagnostics, addressing one of the most significant unmet clinical needs in urology. The foundation of the technology is super resolution ultrasound, which delivers microvascular imaging of the prostate at point of care, providing diagnostic capability without the infrastructure requirements, contraindications or capacity constraints associated with multiparametric MRI — the current standard of care.
Less Grey Imaging operates at the intersection of advanced ultrasound physics, applied mathematics, artificial intelligence and prostate cancer diagnostics, with a clear regulatory pathway and a growing body of clinical data supporting its technology.
unnecessary biopsies today
cancers missed by MRI
More than 1 in 3 positive MRI results are false positives.
From research to real-world clinical impact
Our work is focused on translating advanced imaging science into practical clinical tools. By enabling high-resolution imaging using standard ultrasound systems, we aim to make early prostate cancer detection more accessible, efficient, and scalable across healthcare systems.
The team behind the development of ProViu, combining expertise in ultrasound physics, applied mathematics & AI, and clinical translation. Put (PhD) after all 4 names.
George Papageorgiou
CEO
Vassilis Sboros
CTO
Mairead Butler
Clinical Director
Lachlan Arthur
Scientist/Engineer
Experienced leaders in med-tech, diagnostics and imaging are guiding the company’s strategy and growth.
Tito Bacarese Hamilton
Chair of the board
Nadia Whittley
Non-Executive Director
Colin Roberts
Non-Executive Director
Bill Blair
Non-Executive Director
Trusted by leading clinical centres and supported by recognised innovation bodies and charities.
Less Grey Imaging collaborates with leading hospitals, and innovation bodies to advance prostate cancer diagnostics and validate its technology in real-world clinical settings.
Clinical
Financial
Regulatory
